Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | GHSR | Q92847 | 1/20 | 0.37 |
| ▸ | BMPR2 | Q13873 | 1/20 | 0.36 |
| ▸ | CFD | P00746 | 1/20 | 0.36 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6762831 | 0.90 | CA2 (0.39) | CA9CFDADRA1DADRA1AADRA1B | |
| SCHEMBL7008570 | 0.89 | IKBKB (0.42) | GHSR | |
| Hydrochloric Acid SCHEMBL7012678 | 0.88 | IKBKB (0.42) | GHSR | |
| SCHEMBL7015798 | 0.84 | TLR9 (0.38) | CFDADRA1AADRA1B | |
| SCHEMBL7012049 | 0.83 | HTR7 (0.41) | CFDADRA1DADRA1AADRA1B | |
| SCHEMBL7007077 | 0.83 | EDNRB (0.36) | CFD | |
| SCHEMBL7014517 | 0.83 | — | — | |
| SCHEMBL30449763 | 0.82 | NPY1R (0.36) | CFDADRA1DADRA1AADRA1B | |
| SCHEMBL28350700 | 0.82 | NPY1R (0.36) | CFDADRA1DADRA1AADRA1B | |
| SCHEMBL7014246 | 0.82 | NPY1R (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6169093-B1 | FOR TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | PFIZER INC. | 2001-01-02 | — | — | US | claimed |
| US-6653302-B2 | Benign prostatic hyperplasia | PFIZER INC. | 2003-11-25 | — | — | US | disclosed |
| US-20030130259-A1 | Quinoline and quinazoline compounds useful in therapy | FOX DAVID NATHAN ABRAHAM (GB) | 2003-07-10 | — | — | US | disclosed |
| EP-0968208-B1 | QUINOLINE AND QUINAZOLINE COMPOUNDS USEFUL IN THERAPY, PARTICULARLY IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | PFIZER LTD (GB) | 2003-06-04 | — | — | EP | disclosed |
| US-6521629-B2 | 2-amine substituted quinoline or quinozoline derivatives useful for treating benign prostatic hyperplasia | PFIZER INC. | 2003-02-18 | — | — | US | disclosed |
| CN-1093858-C | Quinoline and quinazoline compounds for the treatment, in particular for the treatment of benign prostatic hyperplasia | PFIZER LTD (US) | 2002-11-06 | — | — | CN | disclosed |
| US-20020040028-A1 | Quinoline and quinazoline compounds useful in therapy | FOX DAVID NATHAN ABRAHAM (GB) | 2002-04-04 | — | — | US | disclosed |
| US-6365599-B1 | FOR THERAPY OF BENIGN PROSTATIC HYPERPLASIA | PFIZER, INC. | 2002-04-02 | — | — | US | disclosed |
| US-6169093-B1 | FOR TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | PFIZER INC. | 2001-01-02 | — | — | US | disclosed |
| CN-1243513-A | Quinoline and quinazoline compounds for the treatment, in particular for the treatment of benign prostatic hyperplasia | PFIZER LTD (US) | 2000-02-02 | — | — | CN | disclosed |
| EP-0968208-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS USEFUL IN THERAPY, PARTICULARLY IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | Pfizer Limited (GB) | 2000-01-05 | — | — | EP | disclosed |
| WO-1998030560-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS USEFUL IN THERAPY, PARTICULARLY IN THE TREATMENT OF BEGNIN PROSTATIC HYPERPLASIA | PFIZER LIMITED (GB) | 1998-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130259-A1 | Quinoline and quinazoline compounds useful in therapy | NQO2, RFT1, LPXN | CA9 1953/4885CA12 3001/4885GHSR 968/4885 |
| US-20020040028-A1 | Quinoline and quinazoline compounds useful in therapy | BPHL, LPXN, NQO2 | CA9 1747/4885CA12 2846/4885GHSR 1109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.